Monaco Asset Management SAM Lowers Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Monaco Asset Management SAM decreased its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 55.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 100,000 shares of the company’s stock after selling 125,000 shares during the quarter. Monaco Asset Management SAM’s holdings in Teva Pharmaceutical Industries were worth $1,676,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 16.4% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,002,472 shares of the company’s stock valued at $16,801,000 after buying an additional 141,143 shares during the last quarter. Metis Global Partners LLC increased its position in Teva Pharmaceutical Industries by 12.8% in the 2nd quarter. Metis Global Partners LLC now owns 15,401 shares of the company’s stock valued at $258,000 after acquiring an additional 1,749 shares during the period. Wedbush Securities Inc. increased its position in Teva Pharmaceutical Industries by 3.3% in the 2nd quarter. Wedbush Securities Inc. now owns 21,995 shares of the company’s stock valued at $369,000 after acquiring an additional 700 shares during the period. Carnegie Lake Advisors LLC raised its stake in Teva Pharmaceutical Industries by 21.7% during the 2nd quarter. Carnegie Lake Advisors LLC now owns 103,850 shares of the company’s stock valued at $1,741,000 after acquiring an additional 18,500 shares during the last quarter. Finally, Sound Shore Management Inc CT lifted its position in Teva Pharmaceutical Industries by 7.2% during the 2nd quarter. Sound Shore Management Inc CT now owns 5,846,512 shares of the company’s stock worth $97,988,000 after acquiring an additional 394,423 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on TEVA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. JPMorgan Chase & Co. boosted their price objective on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday. UBS Group raised their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Finally, Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Buy” and a consensus price target of $25.86.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $24.01 on Friday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $25.00. The firm has a market capitalization of $27.53 billion, a P/E ratio of -150.03, a PEG ratio of 1.11 and a beta of 0.70. The company’s fifty day moving average is $19.74 and its two-hundred day moving average is $17.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.10. The business had revenue of $4.48 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business’s revenue was up 3.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.69 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. Analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.